Successful withdrawal of antiviral treatment in two HBV-related liver
transplant recipients after hepatitis B vaccination with long-term
follow-up

doi:10.1016/j.hbpd.2021.01.003

Abstract
Figure/Table
References (0)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Hepatitis B immunoglobulin (HBIG) combined with nucleos( t)ide analogues (NAs) has become the standard regimen for preventing recurrence of hepatitis B virus (HBV) infection in HBV-related liver transplant (LT) recipients. HBsAg seropositivity was detected in only 7.2%–8.6% of LT recipients who received monotherapy with high-genetic-barrier NAs after a short period of combined therapy [1,2]. Despite progress in the application of newer NAs in HBV-related LT recipients, complete withdrawal of HBV prophylaxis after LT was controversial and considered risky by some centers [3]. We here present two cases of complete and sustained HBV cccDNA-negative status after withdrawal of prophylaxis when intrahepatic and active immune response was achieved with hepatitis B vaccination. Our experience provides a strategy for reliable and safe withdrawal of anti-HBV prophylaxis in HBV-related LT recipients.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles in this journal by
	Xie M
	Zang YJ
	Zhang B
	Rao W

Cite this article:

Xie M, Zang YJ, Zhang B, et al. Successful withdrawal of antiviral treatment in two HBV-related liver transplant recipients after hepatitis B vaccination with long-term follow-up. Hepatobiliary Pancreat Dis Int 2021; 20(6): 595-597. DOI:10.1016/j.hbpd.2021.01.003

URL:

http://dx.doi.org/10.1016/j.hbpd.2021.01.003 OR http://www.hbpdint.com/EN/Y2021/V20/I6/595